期刊
MOLECULAR PHARMACEUTICS
卷 15, 期 2, 页码 527-535出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.molpharmaceut.7b00893
关键词
folic acid-Poloxamer 407 conjugate; folic acid-Poloxamer 407 nanoparticles; nanoparticle disruption; specific drug release; cancer therapy
资金
- Portuguese Foundation for Science and Technology (FCT) [UID/BIO/04469/2013, SFRH/BPD/85790/2012]
- COMPETE [POCI-01-0145-FEDER-006684]
- BioTec-Norte operation - European Regional Development Fund under the scope of Norte-Programa Operational Regional do Norte [NORTE-01-0145-FEDER-000004]
- European Union [NMP-06-2015-683356 FOLSMART]
Novel nanoparticles based on Poloxamer 407 and vegetable oil were produced by high pressure homogenization. Functionalization of those nanoparticles was made by incorporation of folic acid (FA)-Poloxamer 407 conjugate. These nanoparticles showed suitable characteristics for intravenous therapeutic applications similarly to PEGylated albumin-based nanoparticles, previously described by our research group. Here, we found that the absence of albumin at the interface of Poloxamer 407-based nanoparticles improves the overall process of in vitro cellular uptake and nanoparticle disruption inside cancer cells (folate receptor, FR, positive cells). The results presented here suggest that interfacial composition of those nanoparticles is of paramount importance for drug trafficking inside cancer cells.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据